Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1743067 | 0.94 | AQP1 (0.88) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| SCHEMBL21436882 | 0.89 | AQP1 (0.81) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| SCHEMBL12508357 | 0.88 | AQP1 (0.78) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| SCHEMBL31704475 | 0.87 | CA2 (0.84) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| SCHEMBL11374781 | 0.87 | CA2 (0.84) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| SCHEMBL12508361 | 0.87 | AQP1 (0.77) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| Bumetanide SCHEMBL250621 | 0.85 | KDM4E (0.96) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| Bumetanide SCHEMBL27525 | 0.85 | KDM4E (1.00) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| Bumetanide SCHEMBL4425232 | 0.85 | KDM4E (1.00) | AQP1LMNAKDM4EUSP2ALDH1A1 | |
| Bumetanide SCHEMBL29388271 | 0.85 | KDM4E (1.00) | AQP1LMNAKDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616191-B2 | Systems and methods for reversible cryopreservation | UNTIL LABS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250366466-A1 | SYSTEMS AND METHODS FOR REVERSIBLE CRYOPRESERVATION | UNTIL LABS INC. | 2025-12-04 | — | — | US | disclosed |
| US-9248131-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | UNIV ARIZONA STATE (US) | 2015-08-13 | — | — | US | disclosed |
| US-8835491-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-09-16 | — | — | US | disclosed |
| US-20110172195-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2011-07-14 | — | — | US | disclosed |
| US-7906555-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906555-B2 | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080221169-A1 | 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221169-A1 | 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer | ARIZONA BOARD OF REG. ON BEHALF OF THE UNIV. OF AZ (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221169-A1 | 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer | AQP4, AQP3, AQP1 | AQP1 3/4885LMNA 4098/4885KDM4E 3517/4885 |
| US-12616191-B2 | Systems and methods for reversible cryopreservation | TNNC1, CSPP1, TNNI3 | AQP1 107/4885LMNA 526/4885KDM4E 1578/4885 |
| US-20150224108-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | AQP1, AQP4, AQP3 | AQP1 1/4885LMNA 2946/4885KDM4E 4725/4885 |
| US-20110172195-A1 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE | AQP1, AQP4, AQP3 | AQP1 1/4885LMNA 2946/4885KDM4E 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.